Vnitr Lek 2023, 69(3):198-206 | DOI: 10.36290/vnl.2023.034

News in gastroenterology, hepatology and digestive endoscopy

Přemysl Falt1, Dana Ďuricová2, Tomáš Fejfar3, Štěpán Šembera3, Ilja Tachecí3
1 II. interní klinika gastroenterologická a geriatrická, Fakultní nemocnice a Lékařská fakulta Univerzity Palackého v Olomouci
2 Klinické a výzkumné centrum pro střevní záněty, ISCARE, Farmakologický ústav, 1. LF UK, Praha
3 II. interní gastroenterologická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Karlovy v Hradci Králové

Gastroenterology, hepatology and digestive endoscopy are rapidly evolving disciplines with significant advances in the diagnostics and treatment in the entire gastrointestinal tract. The aim of our article was to summarize new perspectives on relevant situations in gastroenterology and hepatology like acute pancreatitis, functional dyspepsia, rational indication of proton pump inhibitors, inflammatory bowel diseases (IBD), cholestatic liver diseases, alcohol induced hepatitis, non-alcoholic fatty live disease (NAFLD) and patophysiology of bilirubin and bile acids. Digestive endoscopy represents an interventional part of gastroenterology and key recent topics are mentioned like pancreatic cancer screening, arteficial intelligence, resection of low-risk neoplastic lesions, enteroscopy techniques, cholangio- and pancreatiscopy and extraluminal expansion of endoscopy techniques by means of endoscopic submucosal and transmural dissection, endoscopic myotomy and lumen apposing stents.

Keywords: gastroenterology, hepatology, digestive endoscopy

Accepted: April 27, 2023; Published: May 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Falt P, Ďuricová D, Fejfar T, Šembera Š, Tachecí I. News in gastroenterology, hepatology and digestive endoscopy. Vnitr Lek. 2023;69(3):198-206. doi: 10.36290/vnl.2023.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. de‑Madaria E, Buxbaum JL, Maisonneuve P, et al. Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis. N Engl J Med. 2022;387(11):989-1000. Go to original source... Go to PubMed...
    2. Manak J. 2022. Těžká akutní pankreatitida. Klinické doporučené postupy [online]. Agentura pro zdravotnický výzkum České republiky (AZV ČR) [Cit. 6. 4. 2023]. Available from: https://kdp.uzis.cz/res/guideline/37-tezka‑akutni‑pankreatitida‑final.pdf
    3. Rej A, Sanders DS, Shaw CC, et al. Efficacy and Acceptability of Dietary Therapies in Non‑Constipated Irritable Bowel Syndrome: A Randomized Trial of Traditional Dietary Advice, the Low FODMAP Diet, and the Gluten‑Free Diet. Clin Gastroenterol Hepatol. 2022;20(12):2876-87 e15. Go to original source... Go to PubMed...
    4. El‑Salhy M, Winkel R, Casen C, et al. Efficacy of Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome at 3 Years After Transplantation. Gastroenterology. 2022;163(4):982-94 e14. Go to original source... Go to PubMed...
    5. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De‑Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022;162(4):1334-42. Go to original source... Go to PubMed...
    6. Grossberg LB, Papamichael K, Cheifetz AS. Review article: emerging drug therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(7):789-804. Go to original source... Go to PubMed...
    7. Pippis EJ, Yacyshyn BR. Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD. Inflamm Bowel, DiS. 2021;27(10):1674-83. Go to original source... Go to PubMed...
    8. Sandborn WJ, Feagan BG, D'Haens G, et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021;385(14):1280-91. Go to original source... Go to PubMed...
    9. Sandborn WJ, Peyrin‑Biroulet L, Sharara AI, et al. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022;20(3):591-601 e8. Go to original source... Go to PubMed...
    10. Feagan BG, Danese S, Loftus EV, Jr., et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2 b/3 double‑blind, randomised, placebo‑controlled trial. Lancet. 2021;397(10292):2372-84. Go to original source... Go to PubMed...
    11. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double‑blind, randomised trials. Lancet. 2022;399(10341):2113-28. Go to original source... Go to PubMed...
    12. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761-806. Go to original source... Go to PubMed...
    13. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of cystic liver diseases. J Hepatol. 2022;77(4):1083-108. Go to original source... Go to PubMed...
    14. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807-24. Go to original source... Go to PubMed...
    15. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines on haemochromatosis. J Hepatol. 2022;77(2):479-502. Go to original source... Go to PubMed...
    16. de Vries E, Bolier R, Goet J, et al. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double‑Blind, Randomized, Placebo‑Controlled Trial. Gastroenterology. 2021;160(3):734-43 e6. Go to original source... Go to PubMed...
    17. Weinberg EM, Dukewich M, Jakhete N, et al. Early Liver Transplantation for Severe Alcohol‑Associated Hepatitis and a History of Prior Liver Decompensation. Am J Gastroenterol. 2022;117(12):1990-8. Go to original source... Go to PubMed...
    18. Murillo Perez CF, Fisher H, Hiu S, et al. Greater Transplant‑Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real‑World External Controls. Gastroenterology. 2022;163(6):1630-42 e3. Go to original source... Go to PubMed...
    19. Zizalova K, Novakova B, Vecka M, et al. Serum concentration of taurochenodeoxycholic acid predicts clinically significant portal hypertension. Liver Int. 2023;43(4):888-95. Go to original source... Go to PubMed...
    20. Woronyczova J, Novakova M, Lenicek M, et al. Serum Bilirubin Concentrations and the Prevalence of Gilbert Syndrome in Elite Athletes. Sports Med Open. 2022;8(1):84. Go to original source... Go to PubMed...
    21. Smid V, Dvorak K, Sedivy P, et al. Effect of Omega-3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatol Commun. 2022;6(6):1336-49. Go to original source... Go to PubMed...
    22. Hur C, Tramontano AC, Dowling EC, et al. Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size: Positive Implications for Future Targeted Screening. Pancreas. 2016;45(7):1062-6. Go to original source... Go to PubMed...
    23. Canto MI, Almario JA, Schulick RD, et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long‑term Surveillance. Gastroenterology. 2018;155(3):740-51 e2. Go to original source... Go to PubMed...
    24. Vaněk P, Zoundjiekpon V, Slodička P, et al. Screening karcinomu pankreatu: Nastal čas vykročit? Gastroenterol Hepatol. 2021;75(5):390-8. Go to original source...
    25. Sharma A, Smyrk TC, Levy MJ, et al. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis. Gastroenterology. 2018;155(2):490-500 e2. Go to original source... Go to PubMed...
    26. Lu Z, Zhang L, Yao L, et al. Assessment of the Role of Artificial Intelligence in the Association Between Time of Day and Colonoscopy Quality. JAMA Netw Open. 2023;6(1):e2253840. Go to original source... Go to PubMed...
    27. Jain S, Seal A, Ojha A, Yazidi A, et al. A deep CNN model for anomaly detection and localization in wireless capsule endoscopy images. Comput Biol Med. 2021;137:104789. Go to original source... Go to PubMed...
    28. Pimentel‑Nunes P, Libanio D, Bastiaansen BAJ, et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2022. Endoscopy. 2022;54(6):591-622. Go to original source... Go to PubMed...
    29. Falt P. Endoscopic treatment of early colorectal cancer. Vnitr Lek. 2022;68(6):355-62. Go to original source... Go to PubMed...
    30. Falt P, Zapletalova J, Urban O. Endoscopic full‑thickness resection versus endoscopic submucosal dissection in the treatment of colonic neoplastic lesions
    31. Papaefthymiou A, Ramai D, Maida M, et al. Performance and safety of motorized spiral enteroscopy: a systematic review and meta‑analysis. Gastrointest Endosc. 2023. Go to original source...
    32. Urban O, Evinova E, Fojtik P, et al. Digital cholangioscopy: the diagnostic yield and impact on management of patients with biliary stricture. Scand J Gastroenterol. 2018;53(10-11):1364-7. Go to original source... Go to PubMed...
    33. Manes G, Paspatis G, Aabakken L, et al. Endoscopic management of common bile duct stones: European Society of Gastrointestinal Endoscopy (ESGE) guideline. Endoscopy. 2019;51(5):472-91. Go to original source... Go to PubMed...
    34. Moons LMG, Bastiaansen BAJ, Richir MC, et al. Endoscopic intermuscular dissection for deep submucosal invasive cancer in the rectum: a new endoscopic approach. Endoscopy. 2022;54(10):993-8. Go to original source... Go to PubMed...
    35. Weusten B, Barret M, Bredenoord AJ, et al. Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020;52(6):498-515. Go to original source... Go to PubMed...
    36. Weusten B, Barret M, Bredenoord AJ, et al. Endoscopic management of gastrointestinal motility disorders - part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020;52(7):600-14. Go to original source... Go to PubMed...
    37. Dolan RD, Bazarbashi AN, McCarty TR, et al. Endoscopic full‑thickness resection of colorectal lesions: a systematic review and meta‑analysis. Gastrointest Endosc. 2022;95(2):216-24 e18. Go to original source... Go to PubMed...
    38. van der Merwe SW, van Wanrooij RLJ, Bronswijk M, et al. Therapeutic endoscopic ultrasound: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2022;54(2):185-205. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.